Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.5850
-0.0170 (-2.82%)
Sep 4, 2026, 3:25 PM EDT - Market open
Citius Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Equivalents | 17.01 | 4.25 | 3.25 | 26.48 | 41.71 | 70.07 |
Cash & Short-Term Investments | 17.01 | 4.25 | 3.25 | 26.48 | 41.71 | 70.07 |
Cash Growth | 179.31% | 30.76% | -87.72% | -36.51% | -40.47% | 405.59% |
Receivables | 0.69 | - | - | - | - | - |
Inventory | 22.63 | 22.29 | 8.27 | - | - | - |
Prepaid Expenses | 3.01 | 1.4 | 2.7 | 7.89 | 2.85 | 2.74 |
Total Current Assets | 43.33 | 27.93 | 14.22 | 34.37 | 44.56 | 72.81 |
Property, Plant & Equipment | 0.75 | 0.82 | 0.25 | 0.46 | 0.65 | 0.83 |
Goodwill | 9.35 | 9.35 | 9.35 | 9.35 | 9.35 | 9.35 |
Other Intangible Assets | 88.79 | 92.8 | 92.8 | 59.4 | 59.4 | 59.4 |
Other Long-Term Assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
Total Assets | 142.26 | 130.94 | 116.65 | 103.61 | 114 | 142.43 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Accounts Payable | 8.04 | 13.69 | 4.93 | 2.93 | 1.17 | 1.28 |
Accrued Expenses | 27.79 | 7.48 | 2.25 | 2.63 | 3.17 | 2.53 |
Short-Term Debt | - | 1 | - | - | - | - |
Current Portion of Leases | 0.18 | 0.09 | 0.24 | 0.22 | 0.2 | 0.18 |
Other Current Liabilities | 15.65 | 22.65 | 28.4 | - | - | - |
Total Current Liabilities | 51.65 | 44.91 | 35.81 | 5.78 | 4.53 | 3.98 |
Long-Term Debt | 6.41 | - | - | - | - | - |
Long-Term Leases | 0.59 | 0.72 | 0.02 | 0.26 | 0.48 | 0.68 |
Long-Term Deferred Tax Liabilities | 7.7 | 7.77 | 6.71 | 6.14 | 5.56 | 4.99 |
Total Liabilities | 66.35 | 53.41 | 42.55 | 12.18 | 10.57 | 9.65 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Common Stock | 0.03 | 0.02 | 0.01 | 0.01 | 0.15 | 0.15 |
Additional Paid-In Capital | 343.7 | 306.34 | 271.44 | 253.06 | 232.37 | 228.08 |
Retained Earnings | -277.12 | -238.8 | -201.37 | -162.23 | -129.69 | -96.05 |
Total Common Equity | 66.61 | 67.55 | 70.08 | 90.83 | 102.83 | 132.18 |
Minority Interest | 9.3 | 9.98 | 4.02 | 0.6 | 0.6 | 0.6 |
Shareholders' Equity | 75.91 | 77.53 | 74.1 | 91.43 | 103.43 | 132.78 |
Total Liabilities & Equity | 142.26 | 130.94 | 116.65 | 103.61 | 114 | 142.43 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Total Debt | 7.18 | 1.81 | 0.26 | 0.48 | 0.68 | 0.86 |
Net Cash (Debt) | 9.83 | 2.44 | 2.99 | 26 | 41.03 | 69.22 |
Net Cash Growth | 133.64% | -18.40% | -88.50% | -36.64% | -40.72% | 453.40% |
Net Cash Per Share | 0.45 | 0.22 | 0.44 | 4.30 | 7.02 | 15.93 |
Filing Date Shares Outstanding | 27.45 | 20.76 | 7.73 | 6.36 | 5.85 | 5.84 |
Total Common Shares Outstanding | 27.45 | 18.07 | 7.25 | 6.35 | 5.85 | 5.84 |
Working Capital | -8.32 | -16.98 | -21.59 | 28.59 | 40.03 | 68.83 |
Book Value Per Share | 2.43 | 3.74 | 9.67 | 14.29 | 17.58 | 22.64 |
Tangible Book Value | -31.52 | -34.6 | -32.07 | 22.08 | 34.08 | 63.44 |
Tangible Book Value Per Share | -1.15 | -1.91 | -4.43 | 3.48 | 5.83 | 10.86 |